TRAVERE THERAPEUTICS, INC. Repayments of Long-Term Debt
TRAVERE THERAPEUTICS, INC. (TVTX) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2021-03-01
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2019-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2018-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2017-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for the quarter ending 2013-06-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for fiscal 2020 was $0.00.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for fiscal 2018 was $40.20M.
- TRAVERE THERAPEUTICS, INC. repayments of long-term debt for fiscal 2017 was $0.00.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month | Repayments of Long-term Debt 22 month | Repayments of Long-term Debt 25 month | Repayments of Long-term Debt 28 month |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | ||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |||||
| 2019-09-30 | $0.00 10-Q · filed 2019-10-30 | ||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $40.20M 10-K · filed 2021-03-01 | |||||
| 2018-09-30 | $40.20M 10-Q · filed 2019-10-30 | ||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $0.00 10-K · filed 2020-02-24 | |||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-01 | ||||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-26 | ||||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-09-16 | $13.20K 10-Q · filed 2013-09-16 | $46.50K 10-Q · filed 2013-09-16 | ||||
| 2013-03-31 | $13.20K 10-Q/A · filed 2013-09-16 | $46.50K 10-Q/A · filed 2013-09-16 | |||||
| 2012-12-31 | $33.30K 10-K/A · filed 2013-09-16 | $33.30K 10-K/A · filed 2013-09-16 | |||||
| 2012-03-31 | $0.00 10-Q/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |